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Abstract
The cholinergic hypothesis of Alzheimer’s disease (AD) has spu-
rred the development of numerous structural classes of compounds
with different pharmacological profiles aimed at increasing cen-
tral cholinergic neurotransmission, thus providing a symptomatic
treatment for this disease. Indeed, the only drugs currently ap-
proved for the treatment of AD cholinomimetics with the phar-
macological profile of acetylcholinesterase inhibitors. Recent evi-
dence of a potential disease modifying role of acetylcholinesterase
inhibitors and M1 muscarinic agonists have led to a revival of
this approach, which might be considered as more than a symp-
tomatic treatment. From one of the research studies (Bratt et al.
1996), arecoline showed significant cognitive improvements in AD
patients, this led to the development of many derivatives in this
class and most of them have either cholinergic toxicity or lack of
specificity to the M1 receptor. Therefore, this paper attempts to
modify different structural problems existing in currently available
arecoline derivatives.
General Introduction to AD
Alzheimer’s disease (AD) is, an irreversible, progressive brain disorder that
occurs gradually and results in memory loss (Fisher 2000), unusual behavior,
personality changes and a decline in thinking abilities. It is a neurodegenera-
tive disorder clinically characterized by progressive loss of cognitive functions,
including memory, language, praxis, judgment and orientation. These losses
are related to the death of brain cells and the breakdown of the connections
between them. Many patients also show significant noncognitive symptoms
such as depression, psychosis, agitation, and personality changes .The etiol-
ogy of AD remains unknown. Several hypotheses (e.g., amyloid deposition,
tau hyperphosphorylation, metabolic dysfunctions, loss of synapses, increased
oxidative stress, immunological changes, and RNA mutations) have been pro-
posed to account for the neurodegenerative process, although the integration
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of all these different hypotheses into one etiopathogenetical cascade requires
further work. One characteristic deficit in AD is the reduction of cholinergic
transmission. Basal forebrain neurons, which provide the majority of cholin-
ergic innervations in the cortex and hippocampus, start to degenerate early
during the course of AD (Growdon 1997). The cortex and hippocampus show
a marked decline in choline acetyltransferase (ChAT), the enzyme responsible
for the synthesis of acetylcholine. The number of basal forebrain neurons and
the level of ChAT have been shown to correlate with the severity of dementia
and the loss of synapses in AD. Recent investigations have documented ad-
ditional cholinergic insufficiencies in other brain regions such as the amyloid
complex and putamen. AD is the most common cause of dementia among
people age 65 and older. The prevalence of AD doubles every 5 years beyond
age 65. Prevalence is the number of people in a population with a disease at
a given time infact, some studies indicate that nearly half of all people ages
85 and older have symptoms of AD (Bratus et al. 1980).
Currently used therapeutic agents
The cholinergic deficit in AD has been a target for pharmacological treatment.
Several possible strategies have been explored (Heidrich and Rosler 1999).
a. Acetylcholine precursors.
b. Choline uptake enhancers.
c. Acetyl group donors.
d. Acetylcholine releasers.
e. Acetylcholinesterase inhibitors.
f. Cholinergic receptor agonists (muscarinic, nicotinic).
Two cholinesterase inhibitors, tacrine and donezepil are currently available
and approved by U.S, Food and Drug Administration (FDA). The efficacy of
acetylcholinesterase inhibitors depends on the availability of sufficient acetyl-
choline and number of presynaptic neurons, which produce and release acetyl-
choline. The availability of presynaptic neurons limits the efficacy of acetyl-
cholinesterase inhibitors in AD, since neurons degenerate with the progression
of the disease. The direct stimulation of cholinergic receptors (muscarinic,
nicotinic) might be more efficient under these circumstances. The investiga-
tion of possible muscarinic receptor agonists began with compounds that were
not specifically designed for use in AD (arecoline, pilocarpine, bethanechol,
oxotremorine). Among these, first generation muscarinic agonists, arecoline
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showed memory enhancing effects in patients with mild to moderate AD.
Arecoline was administered by continuous intravenous infusion. Due to its
rapid invivo hydrolysis, arecoline has a short plasma half-life and negligible ac-
tivity by oral administration, recently a series of arecoline derivatives has been
synthesized with the goal to find compounds (tetrahydropyridinealdoximes,
milameline, or E-1-methyl-1, 2, 5, 6 tetrahydro-pyridine-3-carboxaldehyde-O-
methyloximehydrochloride, CI-979/RU-35926/PD-129409),
with adequate oral activity and a long duration of action. From this new
class of drugs, further studies and possible development of antidementia drug
is required.
Muscarinic receptor1 (M1 receptor) and Alzheimer
disease
M1 receptor is a G protein coupled receptor, is located on outer surface of the
cell membrane of neurons in the brain. It is a glycoprotein with molecular
weight approximately 64 KD. Stimulation of the same will subside the forma-
tion of neurotoxic β amyloid via secondary messengers. Amyloid formation is
an early event in brain’s of AD patients and defines much of the histopathol-
ogy of AD. β Amyloid is deposited in cerebral blood vessels, as they diffuse
to extra cellular space may trigger neuritic reaction. The αβ amyloid frag-
ment deposited in AD brains is neurotoxic where as the N-terminal portion of
APP may have neuroprotective and neurophilic effects formed by stimulation
of M1 receptor (Johnson and Hartigan 1998).
Linkage of M1 receptor, β amyloid and tau phos-
phorylation
The cholinergic hypofunction in AD may lead to the formation of amyloid,
which might impair the coupling of M1 receptor with G proteins (Sadot et al.
1996). This disruption in coupling may lead to formation of amyloid trans-
duction, to a reduction in levels of trophic amyloid precursor protein (αAPPs)
and generation of more β amyloid that can also suppress Ach synthesis and
release, aggravating further cholenergic deficiency (Genis et al. 1999). Tau
microtubule associated protein is neuronal specific and its expression is nec-
essary for neurite outgrowth. Hyperphosphorylation tau proteins in response
to β amyloid, is the principal fibrous component of the neurofibrillary tissue
tangle pathology in AD.
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M1 agonists
As therapeutic agents, M1 agonists in the short term may palliate symptoms
of AD and improve memory function. In long term, M1 agonists have the po-
tential to modify the underlying pathophysiology of AD, and there by prevent
or retard the course of dementia. Several M1 agonists, including AF series
were tested in various animal models. In this context, the M1 agonists from
the AF series restored memory and learning deficits in several animal models
that mimic cholinergic and/or other deficits reported in AD. They also have
the advantage of not producing central and peripheral adverse side effects at
effective doses and showing a relatively wide margin of safety. The therapeu-
tic potential of M1 selective muscarinic agonist including AF102B, AF150 (S),
AF267B (the AF series have basic arecoline structure) is evaluated and com-
pared with several FDA approved acetylcholinestrase inhibitors (Lovestone
and Reynolds 1997). These M1 agonists can elevate APPs, hyperphospho-
rylation in in vitro and in vivo studies, and restore cognitive impairments in
several animal models in AD. Based on the early studies, arecoline had posi-
tive acute effects on some areas of cognition in two small studies. But its uses
are limited because of intravenous administration (gets easily hydrolyzed in
stomach), as a carcinogen and lack of specificity to M1 receptor. Even other
cholinergic agonists including oxtremorine, muscarine, RS86, milameline, and
sabcomeline, which do not discriminate among subtypes of cholinergic recep-
tors. Thus cannot be termed as M1 specific agonists. Some of the tested
M1 agonists like alvameline are very weak agonists of M1 receptor, and also
produces cholinergic adverse reactions like vomiting and increased secretions
(Fisher 2000). The duration of action of the cholinergic drugs is short and
the range of effective doses is small. Currently available agents suffer from,
nonspecificity towards M1 receptor; pose serious adverse side effects, bioavail-
ability problems. Hence, the search of novel orally bioavailable antidementia
drug with improved therapeutic potential over existing agents is of utmost
need.
General structure activity relationship studies of
arecoline bioisters
Extensive database have been developed and continued for better pharmaco-
dynamic and pharmacokinetic parameters. Database developed is as follows:
1. In arecoline (1) ester group is prone to acid hydrolysis in stomach, it
lacks specificity to M1 receptor and also it is carcinogenic according to
studies reported (Nieschulz and Schmersahl 1968).
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2. Quaternization of nitrogen of the arecoline produces equipotent M1
receptor agonist as compared to arecoline itself (Krogsgaard and Bund-
gaard 1991).
3. The secondary amine of norarecoline (absence of CH3 group on ester of
arecoline) is weaker muscarinic agonist (Bieger et al. 1970; Sauerberg
et al. 1986).
4. In case of ester substituent on ester (−COOR), the affinity and biologi-
cal activity increases in this order. Where, the triple bond of propargyl*
ester contributes to the receptor binding (Lambrecht and Mutschler
1981).
R = CH3 < C2H5 < nC3H7 < −CH2 − CH = CH2 <= CH2 − C ≡ CH∗
5. Reduction or removal of the ring double bond (between three and
four position) reduces the muscarinic agonist activity by 250 to 1000
times (In 1, if the nitrogen of the arecoline is substituted by sulphur
(bioisoster, in 1 where N ⇒ S), activity is retained, but not active as
nitrogen in arecoline (Moser et al. 1983).
6. Introduction of another nitrogen in the ring of arecoline, to produce
basic structures that is pyrimidine analogue, which gives less potent
derivatives than arecoline itself (Messer et al. 1992).
7. N − CH3 group of arecoline produces selectivity of the basic structure
to M1 receptor (Moltzen et al. 1994).
8. Substitution at 3rd position of the ring increases the biological activi-
ties but at 4th substitution antagonizes M1 receptor activity and other
substitution doesn’t have significant effect.
The ligand is designed as tertiary nitrogen, which facilitates bioavail-
ability (passage through blood brain barrier), and after the passage the
ligand is
















































Where R1 = H, alkyl, aryl etc; Y=Z=O, N, S
Figure 1: General Structures of arecoline bioisters.
expected to be convert positive nitrogen (Nitrenium ion) in vivo ox-
idation in presence of mono amino oxidase. As supported by struc-
turally related drugs or ligands (Eg. MPTP or Arecoline) and hence
the, molecules will be highly reactive. Because of the above structural
and functional relations to M1 receptor, this basic structure and its
analogues are selected for study.
9. 3-Acetoxy quinuclidines are potent muscarinics and also thianium, pipe-
ridine derivatives of quinuclidine also provides potent muscarinic activ-
ity. An alternative and better strategy to design arecoline derivatives,
is by substituting the ester (because of non-specificity to the receptor,
hydrolysis in the body and carcinogenic in nature) by five or six mem-
bered heterocyclic ring (Lambrecht and Mutschler 1981) to produce
better muscarinic agonist.
In five membered heterocycles 2a
a. Electronegative atom at 1st position increases the biological activity. Or-
der of biological activity with respect to hetero atom, is as follows (Sauer-
berg et al. 1991). N > S > 0.
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b. Presence or absence of electronegative atom at 5th position of the arecoline
ring doesn’t change the biological activity.
c. Electronegative atom as a part of the ring at 4th position, increases the
biological activity, in the order. N > S > O.
d. SR, OR, group attached to 3rd position increases the biological activity.
As the increase in the carbon number of R in SR or OR up to 6 number,
increases the biological activity. [Hydrophobic nature increases binding to
receptor, and avoids being washed out from receptor]
In six membered heterocycles 2b
a. Electronegative atom at 1st position as part of ring of sublead increases
the biological activity, in the order, N > S > O (Ward et al. 1992).
b. Electronegative atom at 4th position as a part of ring of sublead increases
the biological activity, in the order, N > S > 0.
c. SR, OR attached at 3rd position increases the biological activity. As the
increase in the carbon number of R in SR or OR at 2nd position of sublead
up to 6 numbers, increases the agonistic activity.
Different class of arecoline molecules in research and their
muscarinic activity
Arecoline stimulate muscarinic receptor because of its structural similarity




















Arecoline bioisosters have general formulae as shown in 5 and the basic nu-
cleus is tetrahydropyridine.









Both affinity and efficacy are significantly enhanced by tetrahydropyridine
series to M1 receptor, provides semirigid template, which has good affinity
for the muscarinic receptor (Showell et al. 1991). If the molecule is flexible as
that of acetylcholine, it interacts with different class of muscarinic receptors
and lacks the specificity to interact with a specific muscarinic receptor. If
the molecule is rigid, it is unable to stimulate different class of muscarinic
receptors. Tetrahydropyridines are semirigid class can bind specifically to
M1 receptor, also provides some kind of flexibility to stimulate M1 receptor.
N-methyl group on tetrahydropyridines makes the molecule selective towards
M1 than M2 receptor.
I. SAR of arecoline bioisters in which arecoline nu-











Ester linkage is prone to hydrolysis and some of its derivatives are carcino-
genic.
1. When R substituent is H, straight or branched alkyl from one to six carbon
atoms or cycloalkyl from four to eight carbon atoms, muscarinic activity
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increases up to two carbon atoms, beyond which the activity decreases
(Butler et al. 1988).
2. When R substituent is straight or branched alkenyl from one to six car-
bon atoms, as carbon number increases, correspondingly activity also de-
creases.
3. When R is phenyl alkyl where in, the alkyl portion is straight or bran-
ched from one to six carbons and the phenyl ring may be unsubstituted
or substituted with halogen, hydroxy, alkyl from one to six carbon atoms,
or alkyloxy from one to four carbon atoms, muscarinic activity decreases
as the carbon length increases, as the substituted group on phenyl ring
















1. When R1 and R2 are independently hydrogen or alkyl from one to four
carbon atoms, muscarinic activity decreases as carbon length increases in
R1 and R2 independently (Butler et al. 1988).
2. When group R1 is hydrogen and R2 is cycloalkyl from three to eight carbon
atoms, muscarinic activity decreases as the carbon length increases in
cycloalkyl ring.
3. Group R1 is H and group R2 is benzyloxy, it increases the activity (Kelly
et al. 2001).
4. Group R1 is H and group R2 is phenyl alkyl where in, the alkyl portion
is straight or branched from one to six carbon atoms, phenyl ring may be
unsubstituted or substituted with halogen, hydroxy, alkyl from one to six
carbon atoms or alkyloxy from one to four carbon atoms, as carbon length
decreases in alkyl portion and electronegativity of substituent on phenyl
ring increases, proportionately muscarinic activity increases.












1. When R is pyrrolidinyl, piperidinyl, 4-diphenyl methylene piperzinyl, aze-
pinyl, morpholinyl, thiomorpholinyl, isoxazolyl, piperazinyl, pyrrolidinyl
and isoxzolyl rings show good Muscarinic action than six numbered hete-
rocyclic rings.
2. When R is 4-alkyl piperazinyl ring where the alkyl group may be straight
or branched alkyl from one to six carbon atoms, as the carbon length of
alkyl chain increases, muscarinic activity decreases (Bergmeir et al. 1995).










1. When R is straight or branched alkyl chain having one to four carbon
atoms, muscarinic activity decreases as carbon length increases (Bergmeir
et al. 1995).
2. When R1 substituent is straight or branched alkyl from one to six carbon
atoms optionally substituted with hydroxyl or alkoxyl from one to four
carbon atoms, as carbon length of alkyl chain increases and electronega-
tivity of group attached to alkyl chain increases, Proportionally muscarinic
activity increases.
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3. When R1 is cycloalkyl of from three to eight carbon atoms where hydrocar-
bon chain of from one to four carbon atoms, muscarinic activity decreases
as the carbon number increases in cycloalkyl ring.










1. When R is straight or branched alkyl from one to six carbon atoms, option-
ally substituted with hydroxy or alkyl of from one to four carbon atoms,
as carbon length increases, the muscarinic activity also increases (Walther
et al. 1995).
2. Group R is cycloalkyl from three to eight carbon atoms where hydrocarbon
chain of one to four carbon atoms, as ring expands from three to eight
carbon, muscarinic activity decreases.
II. SAR of Arecoline bioisosters in which arecoline
nucleus is attached to different ring systems.













1. When R is unbranched alkyl chain, show strong affinity into binding assay
in rat brain membranes (Ngur et al. 1992).
30 Rangappa et al.
2. When R is branched or a cyclic systems, which are Muscarinic antagonists
and analogs in which the R group contains an ether moiety (e.g. CH2 −
O − CH3) are muscarinic agonist, but they have lower receptor binding
affinity than alkyl derivatives.













1, 2, 5 oxadiazole show M1 receptor efficacy may be related to the magnitude
of electrostatic potential located over the nitrogen’s and also influences the
M1 efficacy of the compounds by determining the energetically favourable
conformers for rotation about bond connecting the tetrahydropyridyl ring
(Ngur et al. 1992).
1. When R is branched or unbranched alkyl chain up to their carbon chain,
central muscarinic affinity increases and R with n-butyl or n-hexyl, show
low affinity to the muscarinic receptor.
2. When R is branched or unbranched alkoxy or alkylthio from one to eight
carbon chain, as the carbon chain increases, a receptor affinity also in-
creases.
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M1 efficacy of 1, 2, 5 thiadiazole analogues are similar to that of 1, 2, 5
oxodiazole analogues (Ngur et al. 1992).
1. When R is alkyl chain from one to eight carbon chain, or branched chain
carbon from three to six carbons, branched alkyl chain with higher carbon
number shows high potency (Sauerberg et al. 1992).
2. When R is alkoxy or alkylthio from one to six carbon chain, among
alkoxy substituents, pentyloxy show maximum receptor affinity, whereas
alkylthio, thiohexyl substituent show greater affinity to muscarinic recep-
tor.
When alkyl R and alkoxy (thioalkyl) R substituent analogues are compared
for their muscarinic activity, either derivative with some carbon length as that
















1. When R1, R2 and R3 are independently unbranched alkyl from one to eight
carbons or branched from three to eight carbons, whereas R2 substituent is
methyl group, it shows high affinity and R1 methyl group shows less affin-
ity, but bulky R2 substituent decreases the muscarinic activity (Moltzen
et al. 1994).
2. When R2 is unsaturated unbranched chain from five to six carbon atoms,
propargyl derivatives show maximum affinity, where as vinyl derivative
shows less affinity to the receptor.












1. When R is unbranched alkyl of from one to six carbon atoms alkyl chain
with less carbon show good affinity with the receptor (Moltzen et al. 1994).
2. When R is alkoxy or thioalkyl from one to six carbon atoms, analogues
with higher carbon show good affinity with the receptor.
3. When R is unsaturated unbranched chain from one to six carbon atoms
while propargyl derivative shows maximum affinity and vinyl with low
affinity to the receptor.
F. Thiophene ring
1. When R is unbranched alkyl chain from one to six carbons, as carbon












2. When R is alkoxy from one to eight carbon, as carbon chain increases up
to seven, agonistic activity increases.












1. When R is unbranched alkyl chain from one to six carbons, as carbon
chain increases muscarinic activity decreases (Ngur et al. 1992).
2. When R is alkoxy from one to eight unbranched carbon chains, as carbon












1. When R is alkoxy from one to eight unbranched carboxyl chain, as carbon
chain increases up to six, muscarinic activity increases (Ngur et al. 1992)
.


















1. When R substituent is alkoxy from one to seven unbranched carbon chain,


















1. Where R is alkoxy or thioalkyl from one to six unbranched carbons, as
carbon length increases, affinity to receptor increases (Lin et al. 1995).
Interaction mechanism of arecoline bioisosteres
with muscarinic receptor-1
Arecoline is a cyclic ’reverse ester’ bioisoster of acetylcholine, containing a
tertiary amino group, it is approximately equipotent with its quatranised
analogue N-methyl arecoline, as a muscarinic Ach receptor agonist, at pH 7.1




Antilog (pH− pka) (1)
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Arecoline is 83% ionized and 17% unionized at pH 7.1. The presence
of a fraction of unionized arecoline molecule (17%) allows it to penetrate
through Blood Brain Barrier and after penetration (figure 2), ionized to form
(protonated form 83%) is assumed to bind and activate muscarinic AChE
receptor-1. Same concept can be applied to arecoline bioisoters (Krogsgaard
and Bundgaard 1991).
Arecoline binds to muscarinic receptor because it is structurally related
to acetylcholine and muscarine, they have similar dimension (4.4A◦ units) be-
tween positively charged nitrogen and oxygen as shown in figure 3. In general
rigid ligands may not have required flexibility to evoke the conformational
change of the receptor protein necessary for a full agonist response, since
































Pk 7.8, PH 7.1
Lipophilic blood brain barrier
Figure 2: Ionization of arecoline and its penetration through blood brain barrier.
The crystal structure of oxadiazole (11) showed that one of the oxygen
atoms of carboxylic acid group of amino acid of the muscarinic receptor forms
a hydrogen bond at N1 with -0- H-N = 2.81A◦ and q = 160.5◦. Acetyl choline
itself cannot form hydrogen bond, but would form an electrostatic interaction
with the aspartate of M1 receptor. In order to probe further into the pocket of
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the receptor, occupied by the acetyl methyl group of acetylcholine (4), various
analogues were synthesized to study the hydrogen bond donating/acceptor
properties of M1 receptor site. The presence of hydroxyl groups as hydrogen
bond donor reduced affinity for both sites of the receptor by approximately
10 fold, whereas fluoro ethyl analogue (designed as a bond acceptor) retained
a more acceptable level of affinity and predicted efficacy. Not only hydrogen
bond donating group is required, but also concomitant secondary lipophilic




























Figure 3: Structured similarities of arecoline, acetylcholine & muscarine
Quantum mechanical calculations revealed difference between the sec-
ondary and tertiary amines of tetrahydropyridines (5). Area of positive elec-
trostatic potential around the protonated ring of nitrogen and have delocal-
ized charge over a wide area including N1, C2 and C6. In contrast the tertiary
amines have more distinct areas of positive charge around the N-methyl group
N1, C2 and C6. The affinity and potency depends mainly on the length of
alkyl chain for space filling properties. The optimum substituents were found
to be unbranched C5−6 alkoxy/alkyl thio side chain. It is probable that this
chain fits into a widening lipophilic cavity in the receptor whose occupancy
is rightly beneficial for activating the M1 receptor. Oxygen and sulfur di-
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rectly attached to the 1, 2, 5 thiadiazole ring (13) probably influence the
electronic and conformational properties of the 1, 2, 5 thiadiazole to obtain
optimum agonist receptor interaction. The length of alkyl chain is proba-
bly also responsible for the separation of the M1 and M2 functional agonist
activity.
Replacement of either one or two nitrogens in the 1, 2, 5 thiadiazole
ring (13) reduced the affinity for the muscarinic agonist conformational state
appropriately 350 fold. The affinity for M1 receptors was also reduced, but
only about 100 fold. A similar reduction in muscarinic receptor affinity was
observed, when N5 nitrogen in 1, 2, 5 oxadiazole is removed. The 1, 2, 5
thiadiazole moiety is largely responsible for the high M1 receptor affinity and
efficacy. Alteration of the aromatic heterocyle led to the compounds with
lower affinity. The sulfur atom in the 1, 2, 5 thiadiazole (13) is apparently
important for the receptor interaction, since the 1, 2, 5 oxadiazole have much
lower M1 receptor affinity. The nitrogens or at least the N5 nitrogen is also
very important for optimal receptor recognition. The exchange of N5 nitrogen
for carbon as in the thiazole (17) caused an even significant decrease in
muscarinic receptor affinity than the sulfur/oxygen exchange.
Exchange of the second nitrogen as in the thiophenes did not alter the re-
ceptor affinity significantly, indicating that the N5 nitrogen perhaps is more
important for receptor interaction than the N3 nitrogen. For the 1, 2, 5-
oxadiazole (12) muscarinic ligands, a correlation between the electrostatic
potentials adjacent to the nitrogens and the receptor affinity has been demon-
strated. For the 1, 2, 5 thiadiazole ligands it was concluded that the methyl
group was the preferred size of lipophilic substituent for binding to the high
affinity state of the receptor. The SAR of the five membered aromatic hetero-
cycles supports the hypothesis that the 1, 2, 5 thiadiazole moiety is a unique
isoster to the arecoline ester functionality.
Quaternary ammonium nitrogen of the acetyl choline or tertiary nitrogen
of the arecoline with muscarinic receptor forms electrostatic attraction (E),
hydrogen bonding (P) with the ester oxygen of acetyl choline or with the ester
oxygen of arecoline, hydrophobic (H) and van der waals (W) interaction with
the methyl group of acetyl choline or arecoline (figure 4).
The essential structure of muscarinic agents is a quaternary ammonium
group and a methyl group. In general, these agents have chain of five atoms
attached to the quaternary nitrogen. One pair of unshared electrons that
can participate in hydrogen bonding and alkyl group, which participate in
hydrophobic and van der waals interactions (Chothia 1970).
(E) = Electrostatic attraction. (P) = Hydrogen bonding.
(H) = Hydrophobic interaction. (W) = Van der Waals interaction.
In 1983, Schulman and co-workers proposed the theoretical model for the
muscarinic receptor. In their model, acetylcholine and cholinergic agents
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interact with a muscarinic receptor through (figure 5) two sites; the anionic
site P and electrophilic site Q. The optimal distance between P and Q [6.7A◦]
is practically invariable in the receptor active conformation (Schulman et
al. 1983). The angle PNOQ (108 degree) defines the drug orientation at
the receptor and owing to structural similarity of agonists, it should remain




























Figure 4: Interaction of acetylcholine or arecoline with muscarinic receptor.
a. Acetylcholine interacting with the receptors carboxylate oxygen and ele-
ctrophilic group, such as a hydrogen-bonding proton.
b. The oxygen is indicated symbolically by P while electrophilic site is located
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at the point of minimum electrostatic potential near the oxygen, denoted













Figure 5: Interaction of acetylcholine and cholinergie agents with muscarinic recep-
tor.
Overview of the SAR
It can be drawn from the above discussion that semirigid ring substituents or
acyl functional groups with variable number of carbon chain and/or alkoxy
(thioalkyl) group with certain number of carbon atoms having electronegative
substitutents placed at proper position and optimization of these substituent
parameters on arecoline lead molecule can help to over come the limitations
of existing molecules tested for A.D.
Glossary
1. Agonist: A drug capable of combining with receptors to initiate drug
action; it possesses affinity and intrinsic activity.
2. Amyloid: A protein (probably combined with chondroitin sulphuric acid)
that is microscopically homogeneous but which is composed of fine fibrils
seen by electron microscope. occurs characteristically as pathologic extra
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cellular deposits beneath the endothelium of capillaries or sinusoids, in the
walls of arterioles, and especially in association with recticuloendothelial
tissue.
3. Blood brain barrier: The walls of the capillaries that perfuse the brain.
4. Cholinergic: Relating to nerve fiber that cause effects similar to those
induced by acetylcholine.
5. Muscarinic: Having muscarine like action, i.e, producing effects that
resemble post ganglionic parasympathetic stimulation.
6. Neuritic: Inflammation of a nerve, marked by neuralgia, hyperesthesia,
anesthesia, or parasthesia, paralysis, muscular atrophy in the region sup-
plied by the effected nerve, and by abolition of the refluxes.
7. Neurophilic (Neurotrophic): Relating to trophic conditions under
nerve influence.
8. Presynaptic neuron: Neuron receiving the signal at a synapse.
9. Putamen: The outer, larger, and darker gray of the three portions into
which the band lenticular nucleus is divided by laminae of white fibers; it
is connected by intervening of gray substance with the caudate nucleus.
10. Receptor: The component of the cell or organism that interact with a
drug and intiates the chain of biochemical events to the drug’s observed
effects.
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